Minerva Neurosciences (FRA:4MNA) Cash-to-Debt : No Debt ⁽¹⁾ (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Minerva Neurosciences Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Minerva Neurosciences's cash to debt ratio for the quarter that ended in Mar. 2024 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Minerva Neurosciences could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Minerva Neurosciences's Cash-to-Debt or its related term are showing as below:

FRA:4MNA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.14 Med: 194.65 Max: No Debt
Current: No Debt

During the past 12 years, Minerva Neurosciences's highest Cash to Debt Ratio was No Debt. The lowest was 0.14. And the median was 194.65.

FRA:4MNA's Cash-to-Debt is ranked better than
99.8% of 1528 companies
in the Biotechnology industry
Industry Median: 6.315 vs FRA:4MNA: No Debt

Minerva Neurosciences Cash-to-Debt Historical Data

The historical data trend for Minerva Neurosciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Minerva Neurosciences Cash-to-Debt Chart

Minerva Neurosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

161.21

229.04

No Debt

Minerva Neurosciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of Minerva Neurosciences's Cash-to-Debt

For the Biotechnology subindustry, Minerva Neurosciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Minerva Neurosciences's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Minerva Neurosciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Minerva Neurosciences's Cash-to-Debt falls into.

Minerva Neurosciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Minerva Neurosciences's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Minerva Neurosciences had no debt ⁽¹⁾.

Minerva Neurosciences's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Minerva Neurosciences had no debt ⁽¹⁾.

Minerva Neurosciences (FRA:4MNA) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Minerva Neurosciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Minerva Neurosciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Minerva Neurosciences (FRA:4MNA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Minerva Neurosciences Inc (FRA:4MNA) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

NERV:USA 4MNA:Germany

Address

1500 District Avenue, Burlington, MA, USA, 01803

Website

https://www.minervaneurosciences.com

Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It primarily focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, major depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and major depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.

Minerva Neurosciences (FRA:4MNA) Headlines

No Headlines

Minerva Neurosciences (FRA:4MNA) Cash-to-Debt : No Debt (1) (As of Mar. 2024)